– Interview with Andrew McCallion, Ph.D., Assistant Professor, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine

Previous articleSepracor In-Licenses Phase III Epilepsy Drug from Bial for $75M Upfront
Next articleImmunoGen Regains Exclusive License to Anticancer Agent from Centocor